Skip to content

SR ONE CAPITAL MANAGEMENT, LP

Follow

13F filer, CIK 1910264, REDWOOD CITY, CA

SR ONE CAPITAL MANAGEMENT, LP reported $1,149,539,649 across 17 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-16. Its ten largest share positions make up 94.01% of the portfolio.

Accepted , ingested 13F-HR 0001012975-26-001062

Period
2026-09-30
Reported value
$1.15B
Holdings
17
Top 10 weight
94.01%
New
3
Sold out
1

Largest buys vs the previous quarter

SecurityShares changeApprox. value
ADRXnew+9,936,661$198M
KRSAnew+613,915$19.6M
ENGNnew+747,750$1.5M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
MANEreduced-321,749-$39M
ENGNexited-747,750-$1.29M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2026

Share positions as resolved from 13F-HR 0001012975-26-001062, largest first. % of portfolio is the value over $1,149,539,649, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
MANEVERADERMICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 2,401,868 shares; 2026Q2: 2,401,868 shares; 2026Q3: 2,080,119 shares 2,080,119$252M21.94%-321,749Timeline
ADRXADARX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 9,936,661 shares 9,936,661$198M17.24%newTimeline
ZBIOZENAS BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 4,911,539 shares; 2025Q1: 4,911,539 shares; 2025Q2: 4,911,539 shares; 2025Q3: 4,911,539 shares; 2025Q4: 5,037,854 shares; 2026Q1: 5,037,854 shares; 2026Q2: 5,037,854 shares; 2026Q3: 5,037,854 shares 5,037,854$136M11.82%0Timeline
CRSPCRISPR THERAPEUTICS AGQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,048,951 shares; 2025Q1: 1,048,951 shares; 2025Q2: 1,048,951 shares; 2025Q3: 2,038,763 shares; 2025Q4: 2,038,763 shares; 2026Q1: 2,038,763 shares; 2026Q2: 2,038,763 shares; 2026Q3: 2,038,763 shares 2,038,763$113M9.81%0Timeline
AVLNAVALYN PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 3,308,649 shares; 2026Q3: 3,308,649 shares 3,308,649$94.3M8.2%0Timeline
ODTXODYSSEY THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 3,794,883 shares; 2026Q3: 3,794,883 shares 3,794,883$84.3M7.34%0Timeline
DSGNDESIGN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 6,526,476 shares; 2025Q1: 6,526,476 shares; 2025Q2: 6,526,476 shares; 2025Q3: 6,526,476 shares; 2025Q4: 6,526,476 shares; 2026Q1: 6,526,476 shares; 2026Q2: 6,526,476 shares; 2026Q3: 6,526,476 shares 6,526,476$82M7.14%0Timeline
ORICORIC PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 4,514,929 shares; 2025Q3: 4,514,929 shares; 2025Q4: 4,514,929 shares; 2026Q1: 4,514,929 shares; 2026Q2: 4,615,384 shares; 2026Q3: 4,615,384 shares 4,615,384$62.2M5.41%0Timeline
MLYSMINERALYS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 2,016,822 shares; 2025Q1: 3,127,933 shares; 2025Q2: 3,127,933 shares; 2025Q3: 2,113,933 shares; 2025Q4: 1,563,966 shares; 2026Q1: 1,563,966 shares; 2026Q2: 1,563,966 shares; 2026Q3: 1,563,966 shares 1,563,966$39.3M3.42%0Timeline
KRSAKORSANA BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 613,915 shares 613,915$19.6M1.71%newTimeline
MOBIMOBIA MED INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,986,072 shares; 2026Q3: 1,986,072 shares 1,986,072$18.8M1.63%0Timeline
SPRYARS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 4,012,903 shares; 2025Q1: 4,012,903 shares; 2025Q2: 4,012,903 shares; 2025Q3: 4,012,903 shares; 2025Q4: 4,012,903 shares; 2026Q1: 4,012,903 shares; 2026Q2: 4,012,903 shares; 2026Q3: 4,012,903 shares 4,012,903$17.3M1.5%0Timeline
ALMSALUMIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,959,896 shares; 2025Q1: 1,959,896 shares; 2025Q2: 1,959,896 shares; 2025Q3: 1,959,896 shares; 2025Q4: 1,959,896 shares; 2026Q1: 1,959,896 shares; 2026Q2: 1,959,896 shares; 2026Q3: 1,959,896 shares 1,959,896$14.5M1.26%0Timeline
NKTXNKARTA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 3,333,333 shares; 2025Q1: 3,333,333 shares; 2025Q2: 3,333,333 shares; 2025Q3: 3,333,333 shares; 2025Q4: 3,333,333 shares; 2026Q1: 3,333,333 shares; 2026Q2: 3,333,333 shares; 2026Q3: 3,333,333 shares 3,333,333$8.73M0.76%0Timeline
OCSOCULIS HOLDING AGQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: 322,500 shares; 2025Q2: 322,500 shares; 2025Q3: 322,500 shares; 2025Q4: 641,022 shares; 2026Q1: 641,022 shares; 2026Q2: 641,022 shares; 2026Q3: 641,022 shares 641,022$5.99M0.52%0Timeline
RAREULTRAGENYX PHARMACEUTICAL INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 137,753 shares; 2026Q1: 137,753 shares; 2026Q2: 137,753 shares; 2026Q3: 137,753 shares 137,753$2.07M0.18%0Timeline
ENGNENGENE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 747,750 shares 747,750$1.5M0.13%newTimeline

Sold out in Q3 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
ENGNENGENE HOLDINGS INC747,750$1.29Mshares

How Q3 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001012975-26-001062 base2026-11-16